Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.

@article{Dann2007RiskadaptedBR,
  title={Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.},
  author={E. Dann and R. Bar-Shalom and A. Tamir and N. Haim and M. Ben-Shachar and I. Avivi and T. Zuckerman and M. Kirschbaum and O. Goor and D. Libster and J. Rowe and R. Epelbaum},
  journal={Blood},
  year={2007},
  volume={109 3},
  pages={
          905-9
        }
}
  • E. Dann, R. Bar-Shalom, +9 authors R. Epelbaum
  • Published 2007
  • Medicine
  • Blood
  • Therapy of Hodgkin disease (HD) is designed to prolong progression-free survival and minimize toxicity. The best regimen to achieve this has not yet been defined. A total of 108 patients with newly diagnosed HD and adverse prognostic factors were prospectively studied between 1999 and 2004. They were assigned to therapy according to defined risk stratification. Patients were defined depending on the International Prognostic Score (IPS). Those with IPS of 3 or higher received 2 cycles of… CONTINUE READING
    Risk, cure and complications in advanced hodgkin disease.
    29

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 31 REFERENCES